Comparative Pharmacology
Head-to-head clinical analysis: ARIPIPRAZOLE versus CAPLYTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIPIPRAZOLE versus CAPLYTA.
ARIPIPRAZOLE vs CAPLYTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.
CAPLYTA (lumateperone) is a second-generation antipsychotic with a unique mechanism of action. It acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. It also functions as a serotonin transporter (SERT) inhibitor and has partial agonist activity at dopamine D1 receptors. Additionally, it modulates glutamate via effects on NMDA receptors and mTOR signaling.
Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.
42 mg orally once daily, with or without food. Initiate at 42 mg/day; no dose titration required.
None Documented
None Documented
Clinical Note
moderateAripiprazole + Torasemide
"Aripiprazole may increase the hypotensive activities of Torasemide."
Clinical Note
moderateAripiprazole + Etacrynic acid
"Aripiprazole may increase the hypotensive activities of Etacrynic acid."
Clinical Note
moderateAripiprazole + Furosemide
"Aripiprazole may increase the hypotensive activities of Furosemide."
Clinical Note
moderateAripiprazole + Bumetanide
"Aripiprazole may increase the hypotensive activities of Bumetanide."
Aripiprazole has a terminal elimination half-life of approximately 75 hours in extensive CYP2D6 metabolizers and about 146 hours in poor metabolizers. The active metabolite, dehydro-aripiprazole, has a half-life of about 94 hours. This long half-life allows for once-daily dosing and gradual achievement of steady state (14 days in extensive metabolizers).
The terminal elimination half-life of lumateperone is approximately 18 hours, supporting once-daily dosing with steady state achieved within 5 days.
Aripiprazole is extensively metabolized primarily by the liver via CYP2D6 and CYP3A4. Approximately 25% of the dose is excreted unchanged in urine, and about 55% in feces. The major metabolite, dehydro-aripiprazole, accounts for about 40% of the AUC and is also excreted in urine and feces.
Following oral administration of lumateperone, approximately 81% of the dose is excreted in feces (mostly as metabolites) and 12% in urine (as metabolites). Less than 1% is excreted unchanged in urine.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic